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tests in apple-allergic patients (n = 2) confi rmed the 
markedly decreased ability of the Mal d 1 mutant to in-
duce allergic reactions in vivo. However, the relevant T 
cell epitopes were present in the mutated molecule ac-
cording to peripheral blood mononuclear cell prolifera-
tion assays.  Conclusions: Our fi ndings suggest that it is 
possible to modulate the IgE-binding properties of aller-
gens by single amino acid substitutions at crucial posi-
tions which might be useful for future immunotherapy 
of birch-pollen-associated food allergies which are not 
ameliorated by birch pollen immunotherapy. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Patients suffering from allergy to birch pollen often 
develop allergic reactions after ingestion of various fruits 
(e.g. apple, pear, peach, cherry), nuts (e.g. hazelnut, wal-
nut), and vegetables (e.g. celery, carrot, potato)  [1–3] . The 
major birch pollen allergen, Bet v 1, and its correspond-
ing homologues in these foods could be identiﬁ ed as the 
cross-reactive molecules mainly responsible for this form 
of food allergy  [4–8] . The deduced amino acid sequence 
of Mal d 1, the major apple allergen, shows 55% identity 
to Bet v 1a (EMBL, Genbank Database access No. 
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 Abstract 
 Background: Individual amino acid residues of the major 
birch pollen allergen, Bet v 1, have been identifi ed to be 
crucial for IgE recognition. The objective of the present 
study was to evaluate whether this concept was appli-
cable   for   the Bet v 1-homologous apple allergen, Mal 
d 1.  Methods: A Mal d 1 fi ve-point mutant was produced 
by PCR techniques, cloned into pMW 172 and expressed 
in  Escherichia coli BL21(DE3) cells. To evaluate the aller-
genic properties of the engineered protein compared to 
Mal d 1 wild-type IgE immunoblotting, ELISA, peripheral 
blood monocytes proliferation assays, and skin prick 
tests were performed.  Results: The Mal d 1 mutant 
showed reduced capacity to bind specifi c IgE as com-
pared to wild-ype Mal d 1 in in vitro assays in the major-
ity of the sera tested. In ELISA, 10 out of 14 serum sam-
ples displayed an 88–30% decrease in IgE binding to Mal 
d 1 mutant compared to wild-type Mal d 1. Skin prick 
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X15877;  [7, 9] ). Cross-inhibition experiments demon-
strated that recombinant Mal d 1 shares IgE epitopes with 
Bet v 1a  [7] . In addition, Mal d 1 also shares T cell epi-
topes with the major birch pollen allergen, Bet v 1  [10] . 
This homology is also reﬂ ected by the clinical observation 
that apple allergy starts after the onset of birch pollinosis 
 [4, 10–12] . The hypothesis suggests that Bet v 1 sensitiza-
tion initiates allergic reactions to Mal d 1. 
 Therefore, one would assume that successful birch pol-
len speciﬁ c immunotherapy (SIT) should also ameliorate 
the symptoms of concomitant apple allergy. However, 
this issue is still controversial, and studies supporting as 
well as contradicting this hypothesis were published  [13–
15] . 
 Previously, we proposed a new concept for the devel-
opment of vaccines for SIT. Using site-directed mutagen-
esis, allergen variants were engineered that display sig-
niﬁ cantly reduced allergenicity in terms of IgE binding 
and thus reducing the risk of developing anaphylactic re-
actions upon injection. On the other hand, these allergen 
mutants are still recognized by T helper cells and can 
therefore modulate the allergic immune response at the 
T cell level, a characteristic shown to be essential for suc-
cessful immunotherapy  [16–18] . 
 Our approach was validated using the Bet v 1 molecule 
and introducing six-point mutations at critical positions. 
The resulting molecule was still recognized by allergen-
speciﬁ c T lymphocytes, but displayed signiﬁ cantly re-
duced IgE binding capacity, as determined by in vivo and 
in vitro tests  [19] . 
 In the present study we investigated whether the ami-
no acid residues/positions shown to be involved in the 
formation of IgE-binding epitopes of Bet v 1 are also cru-
cial for IgE recognition of Mal d 1, the homologous aller-
gen from apple. This was tested using a PCR-based site-
directed mutagenesis approach to produce a Mal d 1mu-
tant protein and to evaluate whether it would represent a 
candidate for SIT in pollen-related apple allergy. 
 Materials and Methods 
 DNA Constructs 
 The cDNA coding for Mal d 1.0108 (EMBL Genbank Database 
access No. AJ417551) was cloned into the pMW172 expression 
vector  [20] as previously described  [7, 21] . The ﬁ ve-point Mal d 1 
mutant was generated using the three-primer PCR mutagenesis 
method  [19] : Thr10 ] Pro; Ile30 ] Val; Thr57 ] Asn; Thr112 ] Cys; 
Ile113 ] Val ( ﬁ g. 1 ). One additional exchange shown to be impor-
tant for IgE recognition of Bet v 1a (position 125, Asp ] Asn) was 
not engineered in the Mal d 1 sequence as asparagine is already 
present in the original wild-type sequence. 
 The oligonucleotides were obtained from MWG Biotech AG 
(Ebersberg, Germany), restriction enzymes from MBI Fermentas 
GmbH (St. Leon-Rot, Germany) and all the other chemicals used 
were purchased from Sigma-Aldrich Chemie (Sleinheim, Ger-
many). 
 Internal Mutagenic Primers 
 M30 5  -AATCTTGGGGAcGAGGTTGTC-3  ; M57 5  -TTCA-
CCAAAAtTGATCTTCTTG-3  ; M112 + 113 5  -GTGGTTCCtgC-
gTCAAGAGCATC-3  . The exchanged bases are in dicated in low-
er case. For mutation at position 10: M10: 5  -GGGCATATGGGT-
GTGTACACCTTCGAGAACGAGTTCcCCTCTG-3  ; Flanking 
primers:  Nde  I (underlined) 5  -GGGCATATGGGTGTGTACA-
CC TTCGAG-3  and  EcoR  I (underlined) 5  -CAAGGAATTC-
TTAGTTGTAGGCATCCGGGTGGTCCTT-3  . 
 The PCR products were digested with  Nde  I and  EcoR  I and 
subcloned in expression vector pMW172. Competent  Escherichia 
coli BL21 cells were transformed with the resulting plasmids. 
 In the following Mal d 1.0108 will be referred to as Mal d 1 wild-
type (Mal d 1wt) and the engineered mutant thereof as Mal d 1 
mutant (Mal d 1mut). 
 Expression and Preparation of   E. coli Cell Lysates of Allergen 
Wild Types and Mutants 
 A single transformant colony of pMW172/Mal d 1wt and 
pMW172/Mal d 1mut, respectively, was picked and grown in 
LB/100 mg/l ampicillin under constant shaking at 37  °  C to an 
OD 600  of 1.0. Expression of recombinant proteins was induced and 
harvested as described previously  [22] . 
 Insoluble inclusion bodies containing rMal d 1wt and rMal 
d 1mut were solubilized in buffer A (20 m M imidazole, pH 7.4/4% 
isopropanol) containing 6  M urea and dialyzed stepwise against 
buffer   A   with   decreasing   urea   concentrations (4  M , 2  M, 1  M, 
0.5  M  ) and ﬁ nal buffer A at 4  °  C (dialysis tubes – Spectra/Por Mem-
brane with MWCO of 10,000, Medicell International Ltd, London, 
UK). Subsequently, the extracts were subjected to further puriﬁ ca-
tion by DEAE chromatography applying a 10  ! 100 mm column 
packed with DEAE-Sepharose Fast ﬂ ow (Amersham, Biosciences, 
Little Chalfont, UK). A linear gradient was performed (buffer A: 
20 m M imidazole pH 7.4/4% isopropanol; buffer B: buffer A/ 
250 m M NaCl; gradient 0–100%) within 100 ml. Afterwards, the 
proteins were puriﬁ ed by separation over a phenyl celluﬁ ne column 
(10  ! 100 mm; Biorad, Hercules, Calif., USA; buffer A: 0.8  M 
NaCl/15 m M NaH 2 PO 4 /10 m M acetic acid pH 4.5; gradient 0–
100% B within 100 ml. Fractions were checked by SDS-PAGE 
analysis and the pure protein fractions pooled and lyophilized. 
 Puriﬁ ed recombinant Bet v 1a [EMBL, Genbank Database ac-
cession No. X15877, referred to here as Bet v 1 wild-type (Bet 
v 1wt)] and Bet v 1 mutant (Bet v 1mut  [19] ) were purchased from 
Biomay (Vienna, Austria). All recombinant allergens were tested 
for bacterium-derived endotoxin levels using a limulus amoebocyte 
lysate assay according to the manufacturer’s instructions (Bio Whit-
taker, Verviers, Belgium). 
 Structural Models of Bet v 1 and Mal d 1 
 The 3D model of Mal d 1 was produced by Swiss Model soft-
ware  [23] using the structure of Bet v 1 as a template (PDB code: 
1BV1) and the sequence alignment of Bet v 1a and Mal d 1.0108 
( ﬁ g. 1 a). 
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 N-Terminal Sequencing 
 Fifty picomoles of puriﬁ ed rMal d 1wt and rMal d 1mut, respec-
tively, were immobilized on polyvinylidene diﬂ uoride (PVDF) 
membranes (ProSorb sample preparation cartridges, Applied Bio-
systems, Foster City, Calif., USA) and analyzed as described  [22] . 
 Matrix-Assisted Laser Desorption/Ionization-Time of Flight 
(MALDI-TOF) Mass Spectrometry 
 For determining intact molecular masses, puriﬁ ed rMal d 1wt 
and rMal d 1mut were ﬁ rst reduced and alkylated. Brieﬂ y, samples 
were dried under vacuum and dissolved in 150   l 0.3  M Tris-HCl, 
pH 8.0, 8  M guanidinium-HCl, 1.3  M EDTA. Dithiothreitol (DTT) 
was added in 50-fold molar excess and samples were incubated for 
4 h at 50  °  C. Afterwards, due to the cysteine residues present in the 
Mal d 1 sequences, 15   mol iodoacetamide was added and alkyla-
tion was performed for 1 h at 37  °  C. The reaction was stopped by 
adding 7.5   mol of DTT. Samples were then extensively dialyzed 
against distilled water and vacuum dried. 
 For mass measurements, 0.5   l (approximately 0.5   g) of re-
duced and alkylated rMal d 1wt and rMal d 1mut proteins were 
analyzed with the Kompact MALDI IV mass spectrometer (Kratos 
Analytical, Manchester, UK) in the linear ﬂ ight mode as described 
previously  [24] . 
 Circular Dichroism Spectra 
 Circular dichroism (CD) measurements of puriﬁ ed rMal d 1wt 
and rMal d 1mut (0.15   g/  l) were performed in aqueous solutions 
using a Jasco J-810 spectropolarimeter (Japan Spectroscopic Co., 
Tokyo, Japan) ﬁ tted with an RTE-111M temperature control sys-
tem (Nes-Lab) as described previously  [25] . 
1 60
Mal d 1.8(AJ417551) GVYTFENEFT SEIPPSRLFK AFVLDADNLI PKIAPQAIKQ AEILEGNGGP GTIKKITFGE
Bet v 1 (X15877) GVFNYETETT SVIPAARLFK AFILDGDNLF PKVAPQAISS VENIEGNGGP GTIKKISFPE
61 120
CV
Mal d 1.8(AJ417551) GSQYGYVKHR IDSIDEASYS YSYTLIEGDA LTDTIEKISY ETKLVACGSG STIKSISH-Y
Bet v 1 (X15877) GFPFKYVKDR VDEVDHTNFK YNYSVIEGGP IGDTLEKISN EIKIVATPDG GSILKISNKY
121 159
Mal d 1.8(AJ417551) HTKGNIEIKE EHVKAGKEKA HGLFKLIESY LKDHPDAYN
Bet v 1 (X15877) HTKGDHEVKA EQVKASKEMG ETLLRAVESY LLAHSDAYN
P V N
a
 Fig. 1.  a Sequence alignment of Mal d 1 and 
Bet v 1 (EMBL Genbank Database acces-
sion numbers are given in brackets). The 
introduced point mutations for Mal d 1mut 
are indicated.  b Ribbon diagram of the Bet 
v 1 structure. The amino acids belonging to 
Mal d 1mut are coloured red while the cor-
responding residues of Bet v 1wt and Mal d 
1wt are coloured white and green, respec-
tively. 
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 Patients and Sera 
 Within a study funded by the European Commission Frame-
work 5, apple-allergic patients were selected in the Netherlands and 
Austria. Dutch patients were recruited at the Department of Der-
matology/Allergology of University Medical Centre Utrecht and 
the Austrian patients at the Medical University of Vienna. All the 
patients reported immediate adverse reactions to apple ingestion 
and the inhalation of birch pollen together with a positive skin prick 
test (SPT) to fresh Golden Delicious apples. According to EAACI 
recommendations  [26], SPT was considered positive if the wheal 
area was 7 mm 2  (3 mm diameter) greater than the negative control. 
Furthermore,   the   sera   selected   for   this   study  (n   =   30)   displayed  
a   positive   RAST to apple ( 1 3.5 IU/ml) as well as to Mal d 1 
( 1 1.8 IU/ml). Sera from healthy donors (n = 5) with  negative case 
histories, negative SPT, and negative RAST were used as controls. 
The study was performed with the approval of the local ethics com-
mittees and with the patients’ consent (or their legal representa-
tives’ consent). 
 SDS-PAGE, IgE Immunoblots and ELISA 
 Puriﬁ ed rMal d 1wt, rMal d 1mut, rBet v 1wt, and rBet v 1mut 
were subjected to 15% SDS-PAGE (2   g/lane)  [27] performed un-
der reducing conditions and either visualized by Coomassie Bril-
liant Blue R-250 staining or further electroblotted onto nitrocellu-
lose membranes  [28] . The IgE-binding abilities of the puriﬁ ed re-
combinant proteins were detected applying sera from food-allergic 
patients (1:  5 diluted in 50 mmol/l sodium phosphate buffer/0.5% 
Tween 20/1% BSA pH 7.5) according to established protocols  [29] . 
Bound IgE was detected by  125 I-labelled antihuman IgE antibodies 
(1:  20 dilution; MALT Allergy System Isotope Reagent, IBL, Ham-
burg, Germany) and visualized by autoradiography. In parallel, the 
serum pool from 5 non-allergic subjects and buffer were used as 
controls. 
 For ELISA experiments the same set of proteins (10   g/ml) was 
dissolved in 25 m M NaHCO 3 , pH 9.6 and coated on microtitre 
wells (Nunc Maxisorp, Nalge Nunc International, Roskilde, Den-
mark) overnight at 4  °  C. Non-speciﬁ c binding sites were blocked 
with 2% milk in TBS/0.05% Tween 20 (v/v). Coated protein was 
incubated with sera from apple-allergic patients (1:  5 dilution) over-
night at 4  °  C. Bound IgE from 14 apple allergic sera (No. 10–23) 
was detected with alkaline-phosphatase-conjugated mouse antihu-
man IgE antibody (1:  1,000; BD-Biosciences Pharmingen, San Di-
ego, Calif., USA) and developed with the  p -nitrophenyl phosphate 
substrate. Colour development was measured using an ELISA read-
er (Spectra Max Plus 384; Molecular Devices GmbH, Munich, Ger-
many) at 405 nm and 510 nm as reference wavelength. Optical 
density (OD) values from normal human serum (n = 5) samples 
were obtained and standard deviation calculated. All OD values 
from serum samples above mean value plus 3 standard deviations 
were considered positive. 
 Titration SPT 
 After obtaining written consent, SPT were performed in 2 ap-
ple-allergic patients on the ﬂ exor aspect of the forearm with fresh 
apple (Golden Delicious) and rMal d 1wt and rMal d 1mut using a 
standardized prick needle (ALK-Lancet, Horsholm, Denmark  [26, 
30] ). Allergen concentrations of 0.02, 0.2, 2, 20 and 100   g/ml were 
applied and SPT reactivity was measured after 15 min by copying 
the wheal reaction with transparent adhesive tape onto a record 
sheet. Subsequently, the wheal area was determined by computer 
scanning  [31] . Histamine dihydrochloride (10 mg/ml) was used as 
a positive control, and the glycerol containing diluents of the SPT 
extract was used as a negative control (ALK-Abelló, Nieuwegein, 
The Netherlands). SPT responses were standardized by dividing 
the original wheal area following  a prick by that obtained for the 
histamine control; a relative wheal area of at least 0.25 SPT/hista-
mine, which is comparable to a reaction of  1 1+ by the standard 
procedure  [26, 31] , was considered positive. 
 Proliferation Assays 
 Peripheral blood mononuclear cells (PBMCs) were obtained 
from birch-pollen-allergic patients with oral allergy syndrome 
(OAS) to apples. Proliferative responses to three different concen-
trations of puriﬁ ed rMal d 1wt and rMal d 1mut (doses: 6.3,  12.5 
and 25   g/ml) were evaluated as described previously  [32] . 
 Results 
 Sequence Analysis and Structural Modelling 
 Recombinant Mal d 1wt and rMal d 1mut were pro-
duced according to established protocols. The ﬁ ve-point 
mutations for Mal d 1mut are marked in the sequence 
alignment ( ﬁ g. 1a ). 
 The 3D model of Mal d 1 was produced (Swiss Model 
software) by using the structure of Bet v 1.2801 (PDB 
code: 1BV1). The model of Mal d 1 (not shown) is almost 
identical to the Bet v 1 structure (rmsd = 1.9 Å for 158 
C  atoms;  ﬁ g. 1b ) with signiﬁ cant differences occurring 
only in a loop joining the   7 strand with C-terminal helix 
  3. Therefore, the structure of Bet v 1 is used in  ﬁ gure 1 b 
to show the location of the exchanged residues belonging 
to Mal d 1mut ( ﬁ g. 1 b). 
 Expression, Puriﬁ cation, and Characterization of 
rMal d 1wt and rMal d 1mut  
 Production in  E. coli yielded 80 mg puriﬁ ed recombi-
nant Mal d 1wt and 40 mg puriﬁ ed Mal d 1mut per litre 
culture, respectively. The proteins appeared as homoge-
neous single bands migrating at 17 kDa as determined by 
SDS-PAGE and Coomassie staining (data not shown). 
N-terminal analysis of both puriﬁ ed proteins revealed 
that the initiating methionine was cleaved off, resulting 
in the ﬁ rst ﬁ ve amino acid residues: GVYTF (data not 
shown) corroborating that the initiating methionine was 
cleaved off according to the side chain length of the pen-
ultimate amino acid  [33] . 
 The integrity of the primary structure was further 
 veriﬁ ed by MALDI-TOF mass spectrometry analy-
sis. The molecular weight of reduced and alkylated 
rMal d 1wt and rMal d 1mut proteins was measured as 
17,556.65 (theoretical 17,549.72) and 17,576.87 (theo-
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retical 17,589.76), respectively. Analysis for endotoxin 
levels yielded 0.23 EU/  g protein for puriﬁ ed rMal d 1wt 
and 0.08 EU/  g protein for rMal d 1mut. These values 
are below the threshold values allowed for human thera-
peutics for parenteral application (e.g. Austrian threshold 
level: 8 EU/ml). 
 CD spectra of rMal d 1wt and rMal d 1mut showed 
that the preparations consisted of folded proteins and that 
the overall secondary structure content of the two pro-
teins was very similar ( ﬁ g. 2 ). On heating to 95  °  C, the 
spectra of rMal d 1mut changed to that of a random coil 
( ﬁ g. 2 b), as usually observed with polypeptides undergo-
ing thermal unfolding. However, rMal d 1wt was not com-
pletely denatured after heating to 95  °  C ( ﬁ g. 2 a). Upon 
cooling to 25  °  C, rMal d 1wt showed a CD spectrum sim-
ilar in shape and peak amplitudes to the one recorded 
before heating, suggesting that rMal d 1wt is able to cor-
rectly refold after thermal denaturation. In contrast, ther-
mally denatured rMal d 1mut was only able to partially 
refold. 
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 Fig. 2. CD spectra of rMal d 1wt ( a ) and 
rMal d 1mut ( b ). Spectra were initially re-
corded at 25  °  C (continuous lines), and after 
heating to 95  °  C (dotted lines) followed by 
cooling to 25  °  C (dashed lines). 
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 Inﬂ uence of Amino Acid Substitutions on Antibody 
Binding 
 To evaluate the antibody-binding properties of the en-
gineered proteins compared to the corresponding wild-
types, we performed immunoblotting experiments. 
 Sera from 9 apple-allergic patients ( ﬁ g. 3 , lanes 1–9) 
were tested in immunoblots for IgE recognition of rMal 
d 1wt and rBet v 1wt ( ﬁ g. 3 a), and rMal d 1mut and rBet 
v 1mut ( ﬁ g. 3 b), respectively. The main band recognized 
by the IgE antibodies from patient sera was detected at 
17 kDa (monomeric form of rMal d 1wt, rMal d 1mut, 
rBet v 1wt, and rBet v 1mut). For some samples, a faint-
er band at approximately 34 kDa was also evident repre-
senting the dimeric forms of rMal d 1wt, rBet v 1wt, and 
kDa
rMal d 1
1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11
rBet v 1
46.0
30.0
21.5
14.3
46.0
30.0
14.3
21.5M
u
ta
n
t
W
ild
-t
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e
a
b
 Fig. 3. Immunoblot analysis of rMal d 1wt 
and rMal d 1mut, rBet v 1wt, and rBet v 
1mut. IgE-binding capacity of puriﬁ ed rMal 
d 1wt and rMal d 1mut ( a ,  b , left), and rBet 
v 1wt and rBet v 1mut ( a ,  b , right) were 
tested with 9 serum samples derived from 
apple-allergic patients (lanes 1–9). A serum 
pool from non-allergic healthy donors (lane 
10) and buffer (lane 11) were run in parallel 
as controls. Bound IgE was detected with 
radiolabelled  125 I-rabbit antihuman IgE an-
tibodies (IBL, Hamburg, Germany). 
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 Fig. 4. IgE ELISA of rMal d 1wt, rMal d 
1mut, rBet v 1wt, and rBet v 1mut. Sera 
from 14 apple-allergic patients (No. 10–23) 
were tested with rMal d 1wt, rBet v 1wt, and 
the mutants thereof. IgE reactivity to the 
mutants is expressed as decrease when com-
pared to IgE binding to the respective wild-
types (100%). Actual OD values are given 
below the ﬁ gure. 
Patient 10 11 12 13 14 15 16 17 18 19 20 21 22 23
rMal d 1wt 3.04 3.44 1.03 0.42 0.68 3.82 1.01 0.53 3.51 1.9 3.63 1.58 0.45 1.3
rMal d 1mut 0.34 2.23 0.72 0.16 0.41 3.27 0.7 0.12 1.43 1.65 2.3 1.38 0.3 1.22
rBet v 1wt 3.96 3.96 3.96 3.96 3.96 3.96 3.96 3.65 3.96 3.61 3.96 3.96 1.92 0.97
rBet v 1mut 0.46 2.07 1.05 1.63 0.77 2.55 1.8 0.41 0.57 1.51 2.17 1.63 0.35 0.92
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rBet v 1mut as it has previously been shown for rBet v 1 
and rApi g 1 ( ﬁ g. 3 a, lanes 2, 5, 9 for rMal d 1wt, lanes 2, 
5, 8, 9 for rBet v 1wt and lanes 5, 9 for rBet v 1mut  [34–
36]) . IgE reactivity to rMal d 1wt was less strong com-
pared to the IgE reactivity to rBet v 1wt. In 7 out of 9 
sera, IgE reactivity to rMal d 1mut and rBet v 1mut was 
clearly reduced ( ﬁ g. 3 , lanes 1–4, 6–8). For controls, either 
normal human serum pool or buffer was used and was 
negative in all experiments ( ﬁ g. 3 a, b, lanes 10–11). 
 The IgE binding activities of rMal d 1wt, rMal d 1mut, 
rBet v 1wt, and rBet v 1mut were also tested by ELISA 
using sera from 14 apple-allergic patients.  Figure 4 shows 
the IgE binding of the mutated proteins compared to the 
wild-types, Mal d 1 as well as Bet v 1 expressed as decrease 
in IgE binding to the mutants when compared to IgE 
binding to the respective wild types as a reference (100%). 
In addition, the actually obtained OD values are given in 
 ﬁ gure 4 . Ten sera displayed a decrease in IgE-binding ac-
tivity to rMal d 1mut of 88–30% when compared to rMal 
d 1wt ( ﬁ g. 4 , serum No. 10–14, 16–18, 20, 22). Three sera 
showed 13% reduction in IgE binding to rMal d 1mut 
( ﬁ g. 4 , serum No. 15, 19, 21) and one sample displayed 
equal IgE reactivity to all four proteins ( ﬁ g. 4 , serum No. 
23). The same set of patients’ sera displayed reduced IgE 
reactivity to Bet v 1mut in the range of 89–35%, with only 
one exception (see above). 
 Titration SPT 
 Two apple-allergic patients were evaluated for their 
skin test reactivity using puriﬁ ed rMal d 1wt and rMal 
d 1mut (0.02, 0.2, 2, 20, and 100   g/ml,  ﬁ g. 5 ; patients 
No. 24 and 25), respectively. Both patients reacted to 
rMal d 1wt and rMal d 1mut in a dose-dependent man-
ner. Patient No. 24 showed a wheal area upon exposure 
to 2–100   g/ml of rMal d 1mut that was 52–82% smaller 
than the wheal induced by rMal d 1wt. In patient No. 25, 
the wheal areas induced by rMal d 1mut were 51–77% 
smaller than those induced by rMal d 1wt. 
 T Cell Proliferation to rMal d 1wt and rMal d 1mut 
Proteins 
 Proliferative responses to different concentrations of 
rMal d 1wt and rMal d 1mut were assessed in PBMCs of 
5 apple-allergic individuals ( table 1 ; patients No. 26–30). 
Medium
cpm!1,000
rMal d 1wt rMal d 1mut
25 g/ml 12.5 g/ml 6.3g/ml 25 g/ml 12.5 g/ml 6.3g/ml
26 0.64 21.63 9.21 2.49 17.00 4.96 5.39
27 31.19 84.82 74.68 62.02 56.53 53.04 51.49
28 12.47 43.32 40.54 37.53 24.15 16.34 11.41
29 2.16 8.20 7.09 6.67 5.80 7.04 7.08
30 3.28 58.48 64.40 61.72 43.01 49.68 38.31
 Table 1. Proliferative responses of PBMC 
of allergic patients (No. 26–30) to puriﬁ ed 
rMal d 1wt and rMal d 1mut 
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 Fig. 5. SPT of puriﬁ ed rMal d 1wt and rMal d 1mut. SPT activity 
was tested in serial dilutions (  g/ml) in 2 patients (patients No. 24, 
25). The wheal areas were determined after 15 min by copying the 
reaction with adhesive tape onto a record sheet, which was then 
analyzed by computer scanning (mm 2 ) and values are presented as 
relative wheal areas in relation to the reaction obtained by hista-
mine dihydrochloride.  a Patient No. 24.  b Patient No. 25. 
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Both proteins induced comparable T cell proliferations 
upon addition of the recombinant proteins. 
 Discussion 
 In this study we could demonstrate that the amino acid 
positions involved in the formation of IgE-binding epit-
opes previously shown for Bet v 1  [19] are also important 
for Mal d 1, the major apple allergen. 
 Mal d 1 consists of a number of isoforms  [37] but, in 
contrast to Bet v 1 isoforms  [38], no signiﬁ cant differ-
ences in IgE-binding activity for individual naturally oc-
curring Mal d 1 isoforms could be identiﬁ ed  [37] . We 
have chosen Mal d 1.0108 (EMBL Genbank Database 
accession No. AJ417551), identical to Mal d 1a at the 
amino acid level (clone GD26 from Golden Delicious, 
EMBL Genbank Database accession No. AF126402  [37] ) 
as the wild type (Mal d 1wt), and obtained a Mal d 1 mu-
tant (Mal d 1mut) by site-directed mutagenesis. Both se-
quences were expressed in  E. coli and puriﬁ ed to homo-
geneity by chromatographic procedures. The integrity of 
the primary structure of the puriﬁ ed proteins was evalu-
ated by mass spectrometry. Our CD spectroscopy exper-
iments showed that the overall secondary structure con-
tents of Mal d 1wt and Mal d 1mut were very similar. 
Thus, it seems that the amino acid substitutions did not 
cause major disturbances in the protein fold and struc-
tural characteristics. 
 Interestingly, the introduced mutations changed the 
thermostability of Mal d 1. In contrast to rMal d 1wt, 
rMal d 1mut did not completely refold after heating to 
95  °  C. Based on statistical examination of structural and 
sequence parameters inﬂ uencing thermostability of pro-
teins preferred and avoided residues in thermophilic pro-
teins can be identiﬁ ed  [39] . In this context the Asn57 and 
Cys112 exchange as well as the Thr10Pro and Ile30Val 
exchange contribute to an overall decrease in the thermo-
stability of rMal d 1mut  [40, 41] . 
 The IgE binding capacity of rMal d 1wt, rMal d 1mut, 
rBet v 1wt, and rBet v 1mut was tested in immunoblots 
using sera from allergic patients. In addition to the major 
band migrating at 17 kDa, an additional, fainter band 
around 34 kDa was detected by speciﬁ c IgE by the more 
sensitive IgE immunoblot. Bet v 1 and homologous pro-
teins tend to form dimers as has been shown for Bet v 1 
and Api g 1 previously  [34–36] . Six out of 9 sera showed 
decreased binding to rMal d 1mut when compared to 
rMal   d   1  wt.   This was also the case when testing rBet 
v 1wt and rBet v 1mut. 
 Performing IgE ELISA, the majority of another set of 
patients’ sera (10/14) tested showed a decrease by 88–
30% in IgE binding to rMal d 1mut compared to rMal 
d 1wt. This effect was reduced in three serum samples 
(decrease by 13%) and was not observed in one sample 
that displayed also no difference when testing IgE binding 
to rBet v 1wt and rBet v 1mut. Again in the case of rBet 
v 1wt, the decrease in IgE binding was more pronounced 
compared to rMol d 1wt. 
 It seems that mutagenesis of the selected ﬁ ve amino 
acid positions in the Mal d 1 sequence did not affect the 
major epitopes recognized by IgE antibodies among a 
subset of patients’ sera tested. Sequence comparison be-
tween Mal d 1 isoform a (synonymous to Mal d 1.01) and 
isoform b (synonymous to Mal d 1.02, EMBL Genbank 
Database accession No. L42952  [37, 42] ) shows that be-
sides the positions selected for mutagenesis they differ in 
12 amino acid positions (9, 16, 40, 47, 70, 78, 82, 98, 107, 
125, 126, and 152). Positions 47, 70, and 98 are identical 
in the Mal d 1 isoforms and Bet v 1a. Thus the remaining 
residues represent unique exchanges associated with the 
Mal d 1b group of isoforms and could lead to the induc-
tion of IgE antibodies directed to additional epitopes not 
inﬂ uenced by the exchanges present in the mutants. Nev-
ertheless, these antibodies might still cross-react with Bet 
v 1a and Mal d 1a isoforms, as our experiments showed. 
If apple-allergic patients are preferentially exposed to Mal 
d 1b isoforms, it would explain why for a small sub-set of 
our patients the introduced mutations did not signiﬁ cant-
ly affect the recognition of Mal d 1. Recently, it has been 
shown by quadrupole time-of-ﬂ ight mass spectrometry 
that natural Mal d 1 contains mostly Mal d 1b-like iso-
forms  [43] . Furthermore, cDNAs coding for Mal d 1b 
(synonymous to Mal d 1.02) are also the most abundant 
Mal d 1 sequences detected in apples  [42] . 
 The in vitro data revealed that IgE binding to rMal 
d 1mut was decreased by 88–13% compared to IgE bind-
ing to rMal d 1wt depending on the serum samples used. 
However, in in vivo tests the hypoallergenic nature of 
rMal d 1mut was demonstrated by skin prick testing of 2 
apple-allergic patients. Compared to rMal d 1wt, rMal 
d 1mut showed a strongly reduced (50–82%) capacity to 
induce typical skin reactions. These results are in good 
agreement with other in vivo tests performed with rMal 
d 1wt and rMal d 1mut by Bolhaar et al.  [44] . 
 In contrast, both recombinant allergens, rMal d 1wt 
and rMal d 1mut were able to activate and induce prolif-
eration of allergen-speciﬁ c T cells from apple-allergic pa-
tients. 
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 So far, relevant IgE epitopes have been determined 
from   the   cherry   homologue, Pru av 1  [45] another Bet 
v 1 homologous food allergen. Similar to Bet v 1, the so-
called p-loop was identiﬁ ed as a crucial B-cell epitope in 
Pru av 1  [46] . A second epitope has recently been de-
scribed by Wiche et al.  [47] , who showed that amino acid 
position 28 was crucial for this epitope which is located 
in the helix 2 area and is clinically relevant to pollen fruit 
cross-reactivity. Despite different amino acid positions, 
these ﬁ ndings are in agreement with our point mutation 
of Ile30Val in Mal d 1mut since they are all part of the 
same secondary structure motif. 
 Although these reports clearly point to hot spots critical 
for IgE binding, no linear epitopes on Bet v 1 have been 
identiﬁ ed so far. Thus, the conserved overall 3D structure 
of the protein seems to be a prerequisite for IgE binding. 
If the structure is disrupted, a dramatic reduction of either 
IgE binding or IgE-dependent reactions can be observed. 
This was shown by the single amino acid exchange Ser 112 
of Pru av 1 by Neudecker et al.  [46] that resulted in an 
unfolded protein  [46] . The recombinant trimer of Bet v 1 
displaying a reduced IgE binding capacity and in vivo al-
lergenic activity is another example of the concept of un-
folded or not properly folded proteins  [48] . It remains to 
be established on a whole range of proteins whether the 
concept of unfolded/misfolded denatured proteins as pos-
tulated by Crameri  [49] or the theory of point-mutated 
proteins targeting the major IgE  epitopes is the method of 
choice for developing hypoallergenic vaccines for SIT for 
the beneﬁ t of the vast majority of allergic patients. 
 In conclusion, the results presented here showed that it 
is possible to decrease the IgE-binding afﬁ nity of epi topes 
by single amino acid substitutions at crucial positions. Re-
combinant Mal d 1mut carrying 5-amino-acid substitu-
tions showed decreased allergenicity in vitro and in vivo 
and conserved antigenicity in terms of T cell recognition 
when testing a number of apple-allergic patients. Our ex-
periments also showed that these 5-amino-acid substitu-
tions affected the overall IgE recognition of Mal d 1. In 
cases where birch pollen immunotherapy based on Bet v 1 
desensitization fails to ameliorate the associated Mal d 1-
induced food-allergic symptoms, the concept of mutated 
hypoallergenic food allergens seems to offer new possibili-
ties. Furthermore, there is a need in the food allergic pop-
ulation to eat the offending food again but without con-
comitant symptoms, since the allergic consumers want to 
extend their daily diet and to intake fresh fruit together 
with vitamins. This has been investigated by a consumer 
survey across Europe  [50] . Thus, the Mal d 1mut described 
here can serve as template for engineering a hypoallergen-
ic vaccine for apple-allergic patients. Injection of such en-
gineered hypoallergens for immunotherapy could modu-
late the allergic immune response at the level of the T help-
er cell, but with a substantially decreased risk of ana -
phylactic (IgE-mediated) side effects during treatment. 
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